The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > ORGANIZATION
ORGANIZATION
- Products from 2nd Round of Development Requests Now Eligible for PDSC Subsidies
June 19, 2012
- Astellas’ Nogimori New Acting President of IFPMA
June 18, 2012
- NPhA Survey: Nearly Half of Pharmacy Operators Have Received No Price Offers from Wholesalers
June 18, 2012
- Generic Market Share Increases Marginally to 23.3% in FY2011: JGA
June 18, 2012
- Drugs Developed in Response to Gov’t Request Should Be Exempted from Downward Foreign Average Price Adjustment: FPMAJ
June 13, 2012
- 48 Products Subjected to Market Expansion Re-Pricing in FY2012: FPMAJ Survey
June 13, 2012
- Products Re-Priced Due to Market Expansion Should Be Eligible for New Drug Premium to Promote Innovation: FPMAJ
June 12, 2012
- FPMAJ’s Subcommittee Calls for Discussion on Need for “Ad Hoc Price Reduction” for Long-Listed Drugs
June 12, 2012
- FPMAJ’s NHI Drug Price Study Committee to Set Up Task Forces for Long-Listed Products, Cost Effectiveness
June 11, 2012
- Chairman Kamoya of FPMAJ’s Committee on NHI Drug Pricing Expresses Concern Over Long-Listed Drugs
June 11, 2012
- JAPMS to Establish Working Group on Improvement of Drug Distribution
June 6, 2012
- JMA Board Members Caution Against Rush to Introduce Cost-Effective Assessment: Dr Suzuki
June 5, 2012
- MREAC to Release Passing Scores for MR Exam Starting This Year
June 4, 2012
- JMA Requests FPMAJ, JPMA to Set Up Nursery Care Facilities for Lectures
June 4, 2012
- Head of Wholesale Industry FTC Calls for Compliance with Competition Code as Violation Cases Increase to Five
May 29, 2012
- Capital Investment Needed for Bar Code Labeling Estimated at About 700 Million Yen Per Drug Maker: JPWA, JPMA Survey
May 28, 2012
- Three Head Office-Level Violations of Fair Competition Code in FY2011: Drug Marketing Industry’s FTC
May 23, 2012
- Greater Centralization, Clarity Needed in Formulating Medical Innovation Policy: Dr Teshirogi of JPMA
May 21, 2012
- Pharma Industry FTC Implements New GL on Restriction of Business Entertaining Rules, Without Acceptance of CAA
May 21, 2012
- JPMA Approves MTPC’s Re-Enrollment 16 Months after Quitting
May 18, 2012
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…